Opioid Dependence Clinical Trial
Official title:
Nanoencapsulated Cannabidiol Time Released Capsules Targeted to Reduce Cravings in the Treatment of Opioid Addiction
Verified date | July 2021 |
Source | Aphios |
Contact | Trevor P Castor |
Phone | 7819326933 |
tcastor[@]aphios.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is determine the safety, efficacy and tolerability of a novel drug APH-1501 as a pharmacotherapy for Opioid Dependence. The investigators will evaluate the safety of escalating doses APH-1501.
Status | Not yet recruiting |
Enrollment | 32 |
Est. completion date | December 2025 |
Est. primary completion date | September 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 55 Years |
Eligibility | Inclusion Criteria: - Ages Eligible for Study: 21 to 55 Years (Adult) - Sexes Eligible for Study: All - Accepts Healthy Volunteers: No - Meets DSM-V criteria with a Substance Use Disorder - Meets protocol-specified criteria for qualification and contraception - Must consent to random assignment, and be willing to commit to medication ingestion. - Is willing and able to remain confined in the study unit for the entire duration of each treatment period and comply with restrictions related food, drink and medications - Voluntarily consents to participate and provides written informed consent prior to any protocol-specific procedures Exclusion Criteria: - Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise: 1. the safety or well-being of the participant or study staff; 2. the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding); 3. the analysis of results - Individuals with clinically significant medical disorders or lab abnormalities. - History of cardiovascular events, head trauma or seizures - Use of any psychoactive drug or medication at any time of study enrollment and participation - Having taken any opioid medication in the last 14 days - Concomitant use of psychotropic medications, with the exception of stable doses (defined as no dosing adjustments in the past two months) of non-monoamine oxidase inhibitor (MAO-I) (antidepressants, non-benzodiazepine anxiolytics, and Attention Deficit -Hyperactivity Disorder(ADHD) medications. - Pregnant or breastfeeding - Not using appropriate contraceptive measures ( hormonal, Nuvo-ring, Depo-Provera, IUD) or other barrier protection. - Psychiatric condition as defined by the DSM-V - Lifetime history of DSM-5 Bipolar I or II Disorder, Schizophrenia or other psychotic disorder. Stably treated Major Depressive Disorder (MDD), Dysthymia, Generalized Anxiety Disorder (GAD), Social Phobia, and Specific Phobia diagnoses are acceptable (i.e. same dose of medication has been prescribed for at least 2 months prior to screening and no changes in current medication expected during course of the trial). - Hypersensitivity to cannabinoids - Suicidal ideation or behavior within the past 6 months. Subjects who are believed to be at suicidal or homicidal risk (answers 'yes' on questions 4 or 5 of C-SSRS) will be referred for assessment by a qualified mental health professional. - Individuals taking an investigational agent within the last 30 days before baseline visit. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Aphios |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | [Safety] Incidence of Treatment Emergent Adverse Effects | Number of patients experiencing treatment emergent Adverse Effects(AE's) and Serious Adverse effects(SAE's) during treatment and follow-up. Patients will be asked to complete the Systematic Assessment for Treatment Emergent Events (SAFTEE)
The SAFTEE is a questionnaire that rates the current severity of a wide range of somatic, behavioral and affective symptoms in general and specific inquiry formats. It is designed to report adverse health events. Contains ~ 25 detailed questions that systematically address 29 body systems. Responses are rated on five levels of severity. |
Baseline through 30 days post final treatment dose up to day 60 | |
Primary | [Tolerability] Pharmacokinetics of APH-1501 | Blood draws to determine the cannabidiol peak plasma concentration (Cmax). | Baseline, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 120 minutes, 180 minutes 240 minutes, 480 minutes post administered dose | |
Primary | [Tolerability] Pharmacokinetics of APH-1501 | Blood draws to determine the cannabidiol time to reach peak serum concentration (Tmax). | Baseline, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 120 minutes, 180 minutes 240 minutes, 480 minutes post first administered dose. | |
Primary | [Tolerability] Pharmacokinetics of APH-1501 | Blood draws to determine the cannabidiol time to derermine serum half life (1/2). | Baseline, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 120 minutes, 180 minutes 240 minutes, 480 minutes post first administered dose. | |
Secondary | Vital signs | Change in Blood pressure - diastolic & systolic (in mmHg). | Baseline, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 120 minutes, 180 minutes 240 minutes, 480 minutes, post first administered dose. | |
Secondary | Vital signs | Change in Heart Rate( beats per minute). | Baseline, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 120 minutes, 180 minutes 240 minutes, 480 minutes, post first administered dose. | |
Secondary | Vital signs | Change in Respiratory (in breaths per minute). | Baseline, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 120 minutes, 180 minutes 240 minutes, 480 minutes, post first administered dose. | |
Secondary | Vital signs | Change in Temp ( in degrees Farenheit). | Baseline, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 120 minutes, 180 minutes 240 minutes, 480 minutes, post first administered dose. | |
Secondary | Vital signs | Change in O2 saturation. | Baseline, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 120 minutes, 180 minutes 240 minutes, 480 minutes, post first administered dose. | |
Secondary | Vital signs | Change in Electrocardiogram (ECG). ( P Wave and QRS Complex) | Baseline, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 120 minutes, 180 minutes 240 minutes, 480 minutes, post first administered dose. | |
Secondary | Vital signs | Change in Blood pressure(in mmHg) diastolic and Systolic. | Day 7,14,21,28 and 60 for followup. | |
Secondary | Vital signs | Change in Heart Rate( beats per minute). | Day 7,14,21,28 and 60 for followup. | |
Secondary | Vital signs | Change in Respiratory (in breaths per minute). | Day 7,14,21,28 and 60 for followup. | |
Secondary | Vital signs | Change in Temp ( in degrees Farenheit). | Day 7,14,21,28 and 60 for followup. | |
Secondary | Vital signs | Change in O2 saturation. | Day 7,14,21,28 and 60 for followup. | |
Secondary | Vital signs | Change in Electrocardiogram ( EKG) P Wave and QRS Complex | Day 7,14,21,28 and 60 for followup. | |
Secondary | Anxiety | Anxiety Assessment using the Beck Anxiety Inventory ( BAI) . The BAI is a self-report measure of anxiety. The total score is calculated by finding the sum of the 21 items. Score of 0-21 = low anxiety Score of 22-35 = moderate anxiety Score of 36 and above = potentially concerning levels of anxiety | Baseline, weeks 1-4 and 1 week post final dose. | |
Secondary | Changes in levels of physiological stress | Measure salivary cortisol levels | Baseline through 30 days post final treatment dose up to day 60 | |
Secondary | Visual Analog Scale for Craving | Changes and potential variations in cue-induced craving will be monitored and measured. | Baseline, weeks 1-4 and 30 days post final treatment up to day 60 | |
Secondary | Clinical Opiate Withdrawal Scale ( COWS) | Changes and variations in common signs and symptoms of opiate withdrawal will be measured and monitor over time. | Baseline, weeks 1-4 adn 30 days post final treatment up to day 60 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03675386 -
Reducing Opioid Use for Chronic Pain Patients Following Surgery
|
N/A | |
Completed |
NCT02593474 -
Medication-Assisted Treatment for Youth With Substance Use Disorders
|
Phase 1 | |
Completed |
NCT02282306 -
Phone Interview to Prevent Recurring Opioid Overdoses
|
N/A | |
Completed |
NCT02294253 -
Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone
|
Phase 2/Phase 3 | |
Completed |
NCT01592461 -
Starting Treatment With Agonist Replacement Therapies Follow-up Study
|
N/A | |
Terminated |
NCT00768482 -
A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence
|
Phase 3 | |
Completed |
NCT01741350 -
Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users
|
N/A | |
Terminated |
NCT04121546 -
Collaborative Care for Opioid Dependence And Pain Pilot Study
|
N/A | |
Withdrawn |
NCT03368794 -
Naloxone to TReatment Entry in the Emergency Setting
|
N/A | |
Completed |
NCT03447743 -
Re-entry XR-NTX for Rural Individuals With Opioid Use Disorder
|
Early Phase 1 | |
Completed |
NCT04464421 -
SMART Effectiveness Trial
|
N/A | |
Recruiting |
NCT04189523 -
Does Early Administration of Ultrasound Guided Regional Anesthesia for Long Bone Fractures Effect Long Term Patient Opioid Usage
|
N/A | |
Completed |
NCT03305666 -
Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures
|
Phase 4 | |
Recruiting |
NCT04003948 -
Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification
|
Phase 2 | |
Terminated |
NCT02935101 -
Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants
|
Phase 2 | |
Completed |
NCT01895270 -
Improving Buprenorphine Detoxification Outcomes With Isradipine
|
Phase 1/Phase 2 | |
Completed |
NCT01717963 -
Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway
|
Phase 3 | |
Completed |
NCT01425060 -
Improving Effective Contraceptive Use Among Opioid-maintained Women
|
Phase 1 | |
Completed |
NCT02324725 -
Biomarkers of Injectable Extended Release Naltrexone Treatment
|
Phase 4 | |
Completed |
NCT01262092 -
Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals
|
Phase 2 |